Zantac Approved For Eradication Therapy In UK

21 November 1994

Glaxo's antiulcerant Zantac (ranitidine) in combination with amoxycillin and metronidazole has been approved in the UK as a treatment for duodenal ulcers associated with Helicobacter pylori infection. The recommended dosage regimen is Zantac 300mg at night plus amoxycillin (750mg three times daily) and metronidazole (500mg three times daily). Glaxo states that the cost per eradication for this therapy will be L37.43 ($59.13) compared to L72.15 for omeprazole dual therapy, the only other eradication therapy approved in the UK.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight